Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17928598 | 0.82 | L3MBTL1 (0.43) | L3MBTL1ALDH1A1KMT2APOLBLMNA | |
| SCHEMBL9131994 | 0.82 | TDP1 (0.50) | L3MBTL1ALDH1A1KMT2APOLBLMNA | |
| SCHEMBL18797 | 0.82 | TDP1 (0.50) | L3MBTL1ALDH1A1KMT2APOLBLMNA | |
| Cyclohexane SCHEMBL28249403 | 0.82 | TDP1 (0.50) | L3MBTL1ALDH1A1KMT2APOLBLMNA | |
| SCHEMBL9134377 | 0.82 | TDP1 (0.50) | L3MBTL1ALDH1A1KMT2APOLBLMNA | |
| SCHEMBL25311355 | 0.82 | TDP1 (0.50) | L3MBTL1ALDH1A1KMT2APOLBLMNA | |
| SCHEMBL2779505 | 0.82 | TDP1 (0.50) | L3MBTL1ALDH1A1KMT2APOLBLMNA | |
| SCHEMBL26914635 | 0.82 | TDP1 (0.50) | L3MBTL1ALDH1A1KMT2APOLBLMNA | |
| SCHEMBL14606391 | 0.81 | KMT2A (0.50) | L3MBTL1ALDH1A1KMT2APOLBEPHX1 | |
| SCHEMBL8099254 | 0.81 | KMT2A (0.50) | L3MBTL1ALDH1A1KMT2APOLBEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090272295-A1 | Coating Materials Consisting of Low- or Medium-Molecular Organic Compounds | CENTRAL GLASS COMPANY, LIMITED (JP) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090272295-A1 | Coating Materials Consisting of Low- or Medium-Molecular Organic Compounds | OXGR1, OXER1, BHMT2 | L3MBTL1 3243/4885ALDH1A1 1479/4885KMT2A 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.